| Pharmaceutical Information |
| Drug Name |
Galsulfase |
| Drug ID |
BADD_D01001 |
| Description |
Galsufase is a variant form of the polymorphic human enzyme N-acetylgalactosamine 4-sulfatase of recombinant DNA origin. Galsulfase is a glycoprotein with a molecular weight of approximately 56 kD. The recombinant protein is comprised of 495 amino acids and contains six asparagine-linked glycosylation sites, four of which carry a bis mannose-6-phosphate manose7 oligosaccharide for specific cellular recognition. Post-translational modification of Cys53 produces the catalytic amino acid residue Ca-formylglycine, which is required for enzyme activity and is conserved in all members of the sulfatase enzyme family. |
| Indications and Usage |
For the treatment of adults and children with Mucopolysaccharidosis VI. |
| Marketing Status |
Prescription |
| ATC Code |
A16AB08 |
| DrugBank ID |
DB01279
|
| KEGG ID |
D06565
|
| MeSH ID |
C508864
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D05UHF
|
| NDC Product Code |
68135-020 |
| Synonyms |
galsulfase | Naglazyme |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
552858-79-4 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
